Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Several studies have suggested that mutations in the RAD51D gene increase a woman’s risk of ovarian cancer, and possibly breast cancer as well. Ongoing research is exploring the extent of that risk, and whether or not a RAD51D mutation increases a person’s risk for other types of cancers.
NCCN guidelines recommend that women with an inherited mutation in RAD51D consider risk-reducing oophorectomy at age 45-50 or earlier based on family history. We recommend consulting with a genetics expert who can assess your personal and family history of cancer, and can help you to determine the best risk-management plan.